Precision medicine: do not neglect the hurdles

Authors

  • Lilla Landeck
  • Patricia Carrigan
  • Khusru Asadullah

DOI:

https://doi.org/10.18063/APM.2016.02.005

Abstract

Tremendous expectations have been connected with precision medicine in the past years. Be-side the advantages that this type of therapy offers we should be aware of its challenges too. In this issue we will highlight on specific challenges that the pharmacological industry is opposed with when de-veloping new targeted therapies. In addition, we will discuss issues with the reproducibility of published scientific data.

References

European Federation of Pharmaceutical Industries and Associations, 2014, The right prevention and treatment for the right patient at the right time: Strategic Research Agenda for Innovative Medicines Initiative 2, accessed December 22, 2015.

Landeck L, Kneip C, Reischl J, et al. 2016, Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology. Experimental Dermatology, 25(5): 333–339.

Wallmark B, 2016, Success factors in drug discovery and development. Advances in Precision Medicine, vol.1(2): 1–5.

Ruppert T, Sydow S and Stock G, 2016, Personalized medicine: consequences for drug research and therapy. Advances in Precision Medicine, vol.1(2): 1–9.

Prinz F, Schlange T, Asadullah K, et al. 2011, Believe it nor not — how much can we rely on published data? Nature Reviews Drug Discovery, vol.10: 712.

Landeck L, Holland R L and Asadullah K, 2016, Advances in precision medicine — time for a new journal. Advances in Precision Medicine, vol.1(1): 1–3.

Bhullar B, 2016, The research data reproducibility problem solicits a 21st century solution. Advances in Precision Medicine, vol.1(2): 1–6.

Bespalov A, Emmerich C H, Gerlach B, et al., 2016, Reproducibility of preclinical data: one man's poison is another man's meat. Advances in Precision Medicine, vol.1(2): 1–10.

Landeck L, Lessl M, Reischl J, et al. 2016, Collaboration for success: the value of strategic collaborations for precision medicine and biomarker discovery. Advances in Precision Medicine, vol.1(1): 25–33.

Landeck L, Lessl M, Busch A, et al. 2016, The role of open innovation in biomarker discovery. Advances in Precision Medicine, vol.1(2): 1–16.

Downloads

Published

2016-10-31

Issue

Vol 1, Issue 2

Section

Editorials

License

Authors contributing to Advances in Precision Medicine agree to publish their articles under the Creative Commons Attribution-Noncommercial 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, that the work is not used for commercial purposes, and that in the event of reuse or distribution, the terms of this license are made clear.